Literature DB >> 1102509

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

S N Sehgal, H Baker, C Vézina.   

Abstract

Rapamycin is a new antifungal antibiotic produced by Streptomyces hygroscopicus NRRL 5491. It was isolated from the mycelium by solvent extraction, purified by silica gel column chromatography and crystallized as a colorless solid which melts at 183 approximately to 185 degrees C and has the empirical formula C56H89NO14. From its characteristic ultraviolet absorption spectrum rapamycin can be classified as a triene. It is highly active against various Candida species, especially Candida albicans. Its activity is compared with that of amphotericin B, candicidin and nystatin.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1102509     DOI： 10.7164/antibiotics.28.727

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  194 in total

Review 1.  Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance.

Authors:  K C Nicolaou; Christopher R H Hale; Christian Nilewski; Heraklidia A Ioannidou
Journal:  Chem Soc Rev       Date:  2012-06-28       Impact factor: 54.564

Review 2.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

Review 3.  Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Curr Protein Pept Sci       Date:  2011-02       Impact factor: 3.272

Review 4.  Natural products as chemical probes.

Authors:  Erin E Carlson
Journal:  ACS Chem Biol       Date:  2010-07-16       Impact factor: 5.100

Review 5.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 6.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

7.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

8.  Caerulomycin A enhances transforming growth factor-β (TGF-β)-Smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs).

Authors:  Rama Krishna Gurram; Weshely Kujur; Sudeep K Maurya; Javed N Agrewala
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

Review 9.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

Review 10.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.

Authors:  Jorge A Garcia; David Danielpour
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.